Entera Bio
ENTX
14 hedge funds and large institutions have $15.9M invested in Entera Bio in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
57% more capital invested
Capital invested by funds: $10.1M → $15.9M (+$5.79M)
5.7% more ownership
Funds ownership: 14.65% → 20.35% (+5.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less funds holding
Funds holding: 17 → 14 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$3.73M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$397K |
| 3 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$272K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.61K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$271K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$39.1K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$30.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$30.2K |
| 5 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$24K |
ENTX Hedge Fund Activity: Q4 2024 in Review
14 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q4 2024, worth a combined $15.9M — up 57% from $10.1M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ENTX and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 5 added.
The largest buyer was Knoll Capital Management, adding an estimated $3.73M. The largest seller was UBS Group, exiting entirely with an estimated $271K sold.
- 14 institutional investors held Entera Bio (ENTX) as of Q4 2024, down from 17 in Q3 2024.
- Funds reported $15.9M of Entera Bio stock for Q4 2024, up 57% quarter-over-quarter.
- 2 funds opened new Entera Bio positions in Q4 2024 and 5 closed out, a net change of -3 holders.
- The largest Entera Bio buyer in Q4 2024 was Knoll Capital Management, an estimated $3.73M added.
- The largest Entera Bio seller in Q4 2024 was UBS Group, an estimated $271K sold.
Based on aggregated 13F filings for Q4 2024.